Search results
USP Biologics™. USP Biologics is prioritizing the ongoing development of state-of-the-art analytical tools, standards and solutions to support regulatory predictability, allowing manufacturers to operate with a high level of confidence and certainty throughout the drug development and approval process across a variety of modalities.
USP currently offers more than 3,500 Reference Standards—highly characterized specimens of drug substances, excipients, food ingredients, impurities, degradation products, dietary supplements, compendial reagents and performance calibrators. Click below to download the full list.
USP–NF is a combination of two compendia, the United States Pharmacopeia (USP) and the National Formulary (NF).
The USP Drug Classification (USP DC 2024) will be published on December 15, 2023, and can be downloaded by completing a short form. This year, the freely accessible version of the USP DC will only include a list of FDA-approved example drugs outside of Medicare Part D, organized by categories and classes.
The United States Pharmacopeia–National Formulary ( USP–NF) is continuously revised. Revisions are presented three times a year in the USP-NF as Issues 1, 2, and 3, and as monthly Accelerated Revisions on the USP website. USP uses its Accelerated Revision processes to expedite revisions to the USP–NF. Accelerated Revisions include ...
The United States Pharmacopeia (USP) is a pharmacopeia (compendium of drug information) for the United States published annually by the over 200-year old United States Pharmacopeial Convention (usually also called the USP), a nonprofit organization that owns the trademark and also owns the copyright on the pharmacopeia itself.
The United States Pharmacopeia : USP 28 : the National Formulary : NF 23 : by authority of the United States Pharmacopeial Convention, Inc., meeting at Washington, D.C., April 12-16, 2000 : United States Pharmacopeial Convention : Free Download, Borrow, and Streaming : Internet Archive.
